SC
CTMX icon

Schulhoff & Co’s CytomX Therapeutics CTMX Stock Holding History

Schulhoff & Co’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.79M Hold
477,550
– – 0.72% 38
2026
Q1 		$2.24M Buy
477,550
+102,700
+27% +$521K 0.92% 30
2025
Q4 		$1.6M Buy
+374,850
New +$1.42M 0.67% 39

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Schulhoff & Co's CTMX Position: Q2 2026 in Review

Schulhoff & Co held its CytomX Therapeutics (CTMX) position steady in Q2 2026 at 477,550 shares worth $1.79M. The position accounts for 0.72% of the portfolio, ranked #38.

Schulhoff & Co first reported a position in CTMX in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.24M in Q1 2026. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Schulhoff & Co held 477,550 shares of CytomX Therapeutics worth $1.79M as of Q2 2026.
  • Schulhoff & Co left its CytomX Therapeutics share count unchanged in Q2 2026.
  • CytomX Therapeutics made up 0.72% of Schulhoff & Co's portfolio in Q2 2026, its #38 holding.
  • Schulhoff & Co first reported a position in CytomX Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Schulhoff & Co's CytomX Therapeutics position peaked at $2.24M in Q1 2026.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Schulhoff & Co's 13F filing for Q2 2026, filed 13 Aug 2026.